Drug retargeting is the discovery of leads and drug candidates via the identification of previously unrecognized molecular activities of approved and investigational drugs.

nPharmakon pursues drug retargeting using methods of computational and experimental chemical biology, using its proprietary computational methods, databases, and compound libraries in collaboration with companies and academic teams specializing in particular indications.

We are interested in diseases and conditions of aging, in particular those involving the central nervous system and skin; and oncology.

Felix Sheinerman PhD, Chief Science Officer
Dmitri Rebatchouk PhD, CEO

Email Contact